Literature DB >> 9829849

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis.

M Funk1, H Schmidt, C Escuriola-Ettingshausen, S Pons, T Dzinaj, C Weimer, B Kornhuber, W Kreuz.   

Abstract

In order to evaluate joint alteration, 17 patients with hemophilia A and B were investigated over a period of 4 years (1993-1997). Patients were subdivided into two groups, according to therapy regimens. In group 1 (n=10) prophylactic treatment was initiated until the third year of life. In group 2 (n=7) patients received prophylactic treatment at the age of 5 years and above. To assess alterations in knee, elbow, and ankle joints, the radiological score and the physical examination score of the Orthopedic Advisory Committee of the World Federation of Hemophilia were used. The sum of the scores of these six joints was defined as the patient-dependent score. Patients of group 1 (median age at the end of observation: 10 years) reached a median radiological score of 1.0 (range: 0-13) and an orthopedic score of 0 (range: 0-4), whereas patients of group 2 (median age: 14 years) had a radiological score of 20 (range: 2-47) and an orthopedic score of 8 (range: 0-12), which shows a significant difference (p <0.01). In both treatment groups a manifestation or progression of arthropathic alteration was seen in those children who had repeated joint bleeding (>5) prior to the onset of prophylactic treatment (r=0.90, p>0.01). Altogether, two of 60 joints in group 1 and 12 of 42 joints in group 2 had a radiological score > or = 4. Elbow joints were more often affected than knee and ankle joints. In conclusion, the number of joint bleedings before prophylactic treatment was started influenced the progression of arthropathy even in patients with early onset of prophylaxis. The aim of treatment in severe hemophilia should be early prophylaxis before repeated joint bleeding occurs in order to prevent osteoarthropathic alteration.

Entities:  

Mesh:

Year:  1998        PMID: 9829849     DOI: 10.1007/s002770050436

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

Review 1.  Current options and new developments in the treatment of haemophilia.

Authors:  Trisha Wong; Michael Recht
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

2.  New treatments in hemophilia: insights for the clinician.

Authors:  Karin Knobe; Erik Berntorp
Journal:  Ther Adv Hematol       Date:  2012-06

3.  Physiotherapy treatment in patients with hemophilia and chronic ankle arthropathy: a systematic review.

Authors:  Rubén Cuesta-Barriuso; Antonia Gómez-Conesa; José Antonio López-Pina
Journal:  Rehabil Res Pract       Date:  2013-08-12

4.  Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.

Authors:  U Martinowitz; T Lissitchkov; A Lubetsky; G Jotov; T Barazani-Brutman; C Voigt; I Jacobs; T Wuerfel; E Santagostino
Journal:  Haemophilia       Date:  2015-05-20       Impact factor: 4.287

Review 5.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.